Cryoglobulin composition before and after PIRR or Peg-IFN-α/RBV therapy in 10 partially responsive patients who reached sustained HCV clearance
| Parameter . | Cryoprecipitate . | |
|---|---|---|
| Before, n = 10 . | After, n = 10 . | |
| HCV RNA, IU/mL | 1 710 466 ± 644 019 | < detection limit |
| IgM, mg/L | 7136 ± 3590 | 5856 ± 5640 |
| IgG, mg/L | 206 ± 97 | 188 ± 36 |
| C3, mg/dL | 16.2 ± 11.0 | 8 ± 5.3 |
| C4, mg/dL | 1.5 ± 0.6 | 2.4 ± 2.1 |
| C1q, mg/dL | 2.9 ± 1.3 | 3.2 ± 1.1 |
| RF activity, IU/mL | 606.7 ± 233 | 404 ± 186.4 |
| Anti-HCV antibody titer, sample/negative ratio | 88 ± 26 | 52 ± 31 |
| Parameter . | Cryoprecipitate . | |
|---|---|---|
| Before, n = 10 . | After, n = 10 . | |
| HCV RNA, IU/mL | 1 710 466 ± 644 019 | < detection limit |
| IgM, mg/L | 7136 ± 3590 | 5856 ± 5640 |
| IgG, mg/L | 206 ± 97 | 188 ± 36 |
| C3, mg/dL | 16.2 ± 11.0 | 8 ± 5.3 |
| C4, mg/dL | 1.5 ± 0.6 | 2.4 ± 2.1 |
| C1q, mg/dL | 2.9 ± 1.3 | 3.2 ± 1.1 |
| RF activity, IU/mL | 606.7 ± 233 | 404 ± 186.4 |
| Anti-HCV antibody titer, sample/negative ratio | 88 ± 26 | 52 ± 31 |